Jaguar continues its sharp strategic focus on its global development program for crofelemer for rare-disease intestinal ...

The FDA is expected to decide on treatments for ADHD, Alzheimer disease, breast cancer, diabetes, and myasthenia gravis.

The European Medicines Agency has backed expanding Namuscla to address muscle rigidity in children and adolescents with rare ...

SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”) a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and ...

In an era marked by mounting drug shortages and a historic shift away from mandatory animal testing, the pharmaceutical landscape is undergoing rapid transformation. Hybrid AI, technology that ...

SAN DIEGO, CA / ACCESS Newswire / April 6, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or ...

The $600,000 AICE-funded project represents a significant contribution toward the overall cost of the Phase I clinical trial of MB-204 and supports the advancement of the program into human trials.

Detailed price information for Shield Therapeutics Plc (SHIEF) from The Globe and Mail including charting and trades.

Under Sharvil Patel, Zydus Lifesciences' pipeline reflects a strategy built on sustained innovation.

Glenmark Pharmaceuticals Inc., USA (Glenmark) today announced that it will manage end-to-end commercialization and distribution for RYALTRIS® (Olopatadine Hydrochloride and Mometasone Furoate) Nasal ...

A TYK2 inhibitor in development shows superior efficacy to placebo and apremilast for treating psoriasis, with no new safety ...

SAN DIEGO, CA / ACCESS Newswire / April 6, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to ...